Shanon and William Schmidtknecht, of Poynette, filed their lawsuit in federal court in Milwaukee on Jan. 21, a year to the ...

Objective: To test the hypothesis that once-daily treatment with fluticasone propionate is as effective as twice-daily treatment in children with well controlled asthma. Design: Multicentre ...

GlaxoSmithKline "deliberately" discontinued a widely-used asthma medication in order to reap profits and families suffered, ...

The state’s top lawyer accused a British multinational drug company of “deceptive and unfair practices” that endangered lives and exploited American taxpayers.

The lawsuit filed in Maricopa County Superior Court contends GlaxoSmithKline's actions violate the Arizona Consumer Fraud Act ...

HealthDay News — In a clinical guideline issued by the American College of Gastroenterology and published in the January issue of the American Journal of Gastroenterology, recommendations are ...

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced preliminary unaudited XHANCE ® (fluticasone ...

Group sales fell 4 per cent to £5.6 billion ($9.5 billion) in the second quarter, with Advair/Seretide (fluticasone propionate and salmeterol) hit harder than expected by increasing competition ...

fluticasone propionate and short-acting beta agonist (SABA) albuterol sulfate. The drug – delivered using a proprietary Teva inhaler – could become the first ICS/SABA for both the adult and ...

driven by sustained growth in prescriptions for XHANCE® (fluticasone propionate). “Our preliminary unaudited fourth quarter net product revenue of $22.4 million is in line with our prior ...

today announced preliminary unaudited XHANCE® (fluticasone propionate) net product revenue of $22.4 million for the three months ended December 31, 2024. “Our preliminary unaudited fourth ...